Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
Objective It has been proved that glucagon-like peptide-1 receptor (GLP1R) agonists have positive effects on renal outcomes in diabetic patients. However, it remains unknown whether GLP1R agonists could provide similar protection against other kidney diseases.Methods We performed two-sample Mendelia...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Taylor & Francis Group
2025-12-01
|
| Серія: | Renal Failure |
| Предмети: | |
| Онлайн доступ: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2478488 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|